Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2025)

Historic Assets Average for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $278.7 million.

  • Amylyx Pharmaceuticals' Assets Average fell 438.1% to $278.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.7 million, marking a year-over-year decrease of 438.1%. This contributed to the annual value of $355.5 million for FY2024, which is 2176.45% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Assets Average is $278.7 million, which was down 438.1% from $207.1 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Assets Average peaked at $492.0 million during Q4 2023, and registered a low of $190.0 million during Q1 2022.
  • Over the past 4 years, Amylyx Pharmaceuticals' median Assets Average value was $286.4 million (recorded in 2022), while the average stood at $317.4 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Assets Average soared by 12626.27% in 2023 and then crashed by 5579.15% in 2025.
  • Over the past 4 years, Amylyx Pharmaceuticals' Assets Average (Quarter) stood at $286.4 million in 2022, then soared by 71.77% to $492.0 million in 2023, then tumbled by 54.84% to $222.2 million in 2024, then increased by 25.43% to $278.7 million in 2025.
  • Its Assets Average was $278.7 million in Q3 2025, compared to $207.1 million in Q2 2025 and $206.7 million in Q1 2025.